Leerink Swann reaffirms Stryker’s ‘outperform’ rating — 5 notes

Leerink Swann analysts reaffirmed Stryker stock’s “outperform” rating, according to the Legacy.

Advertisement

Here are five notes:

 

1. Leerink Swann gave Stryker stock a target price of $110.

 

2. Leerink Swann projects a potential upside of 8.3 percent from Stryker’s previous close.

 

3. Stryker shares traded up 0.01 percent on Monday, hitting $101.62.

 

4. Stryker has a one year low of $77.87 and a one year high of $103.99.

 

5. The company has a market cap of $38.3 billion and a P/E ratio of 41.7.

 

More articles on devices:
Nevro announces positive results from SENZA system study: 5 insights
Smith & Nephew to build US headquarters in Fort Worth: 5 things to know
Is Stryker next for a big transaction? 7 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.